Genetic susceptibility to bladder cancer risk and outcome

Personalized Medicine

Volumn 8, Issue 3, 2011, Pages 365-374

  Gu, Jian ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCG; bladder cancer; candidate gene approach; genetic susceptibility; genome wide association study; single nucleotide polymorphism

Indexed keywords

ACYLTRANSFERASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; MYC PROTEIN; PROSTATE STEM CELL ANTIGEN;

BLADDER CANCER; CANCER RISK; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 2Q; CHROMOSOME 3Q; CHROMOSOME 4P; CHROMOSOME 5P; CHROMOSOME 8Q; DNA REPAIR; GENE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TERT GENE; TP63 GENE;

EID: 79958108698     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.15     Document Type: Review

References (95)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Wu X, Ros MM, Gu J, Kiemeney L: Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 102(9 Pt B), 1207-1215 (2008).
3. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89(3), 630-639 (2000). (Pubitemid 30640110)
4. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP: A meta-analysis on the association between bladder cancer and occupation. Scand. J. Urol. Nephrol. Suppl. (218), 64-78 (2008).
5. Villanueva CM, Cantor KP, Cordier S, et al.: Disinfection byproducts and bladder cancer: a pooled analysis. Epidemiology 15(3), 357-367 (2004). (Pubitemid 40416958)
6. Villanueva CM, Cantor KP, King WD, et al.: Total and specific fluid consumption as determinants of bladder cancer risk. Int. J. Cancer 118(8), 2040-2047 (2006).
7. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY: A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br. J. Cancer 53(3), 399-405 (1986).
8. Aben KK, Witjes JA, Schoenberg MP, et al.: Familial aggregation of urothelial cell carcinoma. Int. J. Cancer 98(2), 274-278 (2002). (Pubitemid 34150813)
9. Kramer AA, Graham S, Burnett WS, Nasca P: Familial aggregation of bladder cancer stratified by smoking status. Epidemiology 2(2), 145-148 (1991).
10. Lichtenstein P, Holm NV, Verkasalo PK, et al.: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000). (Pubitemid 30451850)
11. Aben KK, Baglietto L, Baffoe-Bonnie A, et al.: Segregation analysis of urothelial cell carcinoma. Eur. J. Cancer 42(10), 1428-1433 (2006). (Pubitemid 43903162)
12. Garcia-Closas M, Malats N, Silverman D, et al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486), 649-659 (2005). (Pubitemid 41176017)
13. Gu J, Liang D, Wang Y, Lu C, Wu X: Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat. Res. 581(1-2), 97-104 (2005). (Pubitemid 40255898)
14. Stern MC, Lin J, Figueroa JD, et al.: Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 69(17), 6857-6864 (2009).
15. Kiemeney LA, Thorlacius S, Sulem P, et al.: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40(11), 1307-1312 (2008).
16. Wu X, Ye Y, Kiemeney LA, et al.: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet. 41(9), 991-995 (2009).
17. Kiemeney LA, Sulem P, Besenbacher S, et al.: A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet. 42(5), 415-419 (2010).
18. Rafnar T, Sulem P, Stacey SN, et al.: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41(2), 221-227 (2009).
19. Rothman N, Garcia-Closas M, Chatterjee N, et al.: A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42(11), 978-984 (2010).
20. Grotenhuis AJ, Vermeulen SH, Kiemeney LA: Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol. 6(9), 1433-1460 (2010).
21. Wu X, Lin X, Dinney CP, Gu J, Grossman HB: Genetic polymorphism in bladder cancer. Front Biosci. 12, 192-213 (2007). (Pubitemid 46852836)
22. Horikawa Y, Gu J, Wu X: Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. Curr. Opin. Urol. 18(5), 493-498 (2008).
23. Malats N: Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression. Scand. J. Urol. Nephrol. Suppl. (218), 131-140 (2008).
24. Vatsis KP, Weber WW, Bell DA, et al.: Nomenclature for N-acetyltransferases. Pharmacogenetics 5(1), 1-17 (1995).
25. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507, 65-77 (2002). (Pubitemid 35286541)
26. Agundez JA: Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab. 9(6), 520-531 (2008). (Pubitemid 352025183)
27. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U: Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299(20), 2423-2436 (2008). (Pubitemid 351749241)
28. Yeager M, Chatterjee N, Ciampa J, et al.: Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat. Genet. 41(10), 1055-1057 (2009).
29. Chung CC, Magalhaes WC, Gonzalez-Bosquet J, Chanock SJ: Genome-wide association studies in cancer - current and future directions. Carcinogenesis 31(1), 111-120 (2010).
30. Ghoussaini M, Song H, Koessler T, et al.: Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl Cancer Inst. 100(13), 962-966 (2008). (Pubitemid 351957516)
31. Eeles RA, Kote-Jarai Z, Al Olama AA, et al.: Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41(10), 1116-1121 (2009).
32. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al.: Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42(2), 132-136 (2010).
33. Tomlinson IP, Webb E, Carvajal-Carmona L, et al.: A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40(5), 623-630 (2008). (Pubitemid 351601204)
34. Easton DF, Pooley KA, Dunning AM, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007). (Pubitemid 47014426)
35. Zanke BW, Greenwood CM, Rangrej J, et al.: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39(8), 989-994 (2007). (Pubitemid 47185183)
36. Yeager M, Orr N, Hayes RB, et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007). (Pubitemid 46676108)
37. Wu X, Hildebrandt MA, Chang DW: Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 28(3-4), 269-280 (2009).
38. Cortessis VK, Yuan JM, Van Den Berg D, et al.: Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study. Cancer Epidemiol. Biomarkers Prev. 19(12), 3150-3156 (2010).
39. Wang M, Zhang W, Yuan L, Fu G, Wei Q, Zhang Z: Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 30(6), 991-996 (2009).
40. Ahmadiyeh N, Pomerantz MM, Grisanzio C, et al.: 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl Acad. Sci. USA 107(21), 9742-9746 (2010).
41. Pomerantz MM, Ahmadiyeh N, Jia L, et al.: The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 41(8), 882-884 (2009).
42. Sotelo J, Esposito D, Duhagon MA, et al.: Long-range enhancers on 8q24 regulate c-Myc. Proc. Natl Acad. Sci. USA 107(7), 3001-3005 (2010).
43. Wasserman NF, Aneas I, Nobrega MA: An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res. 20(9), 1191-1197 (2010).
44. Lehmann ML, Selinski S, Blaszkewicz M, et al.: Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch. Toxicol. 84(12), 967-978 (2010).
45. Stern MC, Van Den Berg D, Yuan JM, et al.: Sequence variant on 3q28 and urinary bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study. Cancer Epidemiol. Biomarkers Prev. 18(11), 3057-3061 (2009).
46. Comperat E, Bieche I, Dargere D, et al.: p63 gene expression study and early bladder carcinogenesis. Urology 70(3), 459-462 (2007). (Pubitemid 47464492)
47. Urist MJ, Di Como CJ, Lu ML, et al.: Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161(4), 1199-1206 (2002).
48. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C: Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63(6), 1079-1083 (2004). (Pubitemid 38746807)
49. Wang S, Tang J, Wang M, Yuan L, Zhang Z: Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis 31(4), 621-624 (2010).
50. Amara N, Palapattu GS, Schrage M, et al.: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 61(12), 4660-4665 (2001). (Pubitemid 32691871)
51. Elsamman E, Fukumori T, Kasai T, et al.: Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 97(6), 1202-1207 (2006). (Pubitemid 43907322)
52. Sakamoto H, Yoshimura K, Saeki N, et al.: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40(6), 730-740 (2008). (Pubitemid 351748870)
53. Bahrenberg G, Brauers A, Joost HG, Jakse G: Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun. 275(3), 783-788 (2000).
54. Reiter RE, Gu Z, Watabe T, et al.: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95(4), 1735-1740 (1998). (Pubitemid 28103463)
55. Pandith AA, Shah ZA, Siddiqi MA: Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol. Oncol. (2010) (Epub ahead of print).
56. Baird DM: Variation at the TERT locus and predisposition for cancer. Expert Rev. Mol. Med. 12, e16 (2010).
57. Petersen GM, Amundadottir L, Fuchs CS, et al.: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42(3), 224-228 (2010).
58. Shete S, Hosking FJ, Robertson LB, et al.: Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41(8), 899-904 (2009).
59. Stacey SN, Sulem P, Masson G, et al.: New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41(8), 909-914 (2009).
60. Wang Y, Broderick P, Webb E, et al.: Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40(12), 1407-1409 (2008).
61. Pooley KA, Tyrer J, Shah M, et al.: No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. Cancer Epidemiol. Biomarkers Prev. 19(7), 1862-1865 (2010).
62. Schraml P, Bucher C, Bissig H, et al.: Cyclin E overexpression and amplification in human tumours. J. Pathol. 200(3), 375-382 (2003). (Pubitemid 36827312)
63. Mackenzie PI, Owens IS, Burchell B, et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7(4), 255-269 (1997). (Pubitemid 27358064)
64. Perera MA, Innocenti F, Ratain MJ: Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy 28(6), 755-768 (2008). (Pubitemid 351975379)
65. Giuliani L, Gazzaniga P, Caporuscio F, Ciotti M, Frati L, Agliano AM: Can down-regulation of UDP-glucuronosyltransferases in the urinary bladder tissue impact the risk of chemical carcinogenesis? Int. J. Cancer 91(1), 141-143 (2001).
66. Iida K, Mimura J, Itoh K, et al.: Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice. J. Biochem. 147(3), 353-360 (2010).
67. Dinney CP, McConkey DJ, Millikan RE, et al.: Focus on bladder cancer. Cancer Cell 6(2), 111-116 (2004). (Pubitemid 39485683)
68. Bakkar AA, Wallerand H, Radvanyi F, et al.: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63(23), 8108-8112 (2003). (Pubitemid 37549454)
69. Kurth K, Denis L, Sylvester R, de Pauw M: The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. Prog. Clin. Biol. Res. 378, 1-7 (1992).
70. Pashos CL, Botteman MF, Laskin BL, Redaelli A: Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 10(6), 311-322 (2002). (Pubitemid 35231626)
71. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG: Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J. Urol. 162(5), 1697-1701 (1999). (Pubitemid 29474702)
72. Gontero P, Bohle A, Malmstrom PU, et al.: The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol. 57(3), 410-429 (2010).
73. Williams SK, Hoenig DM, Ghavamian R, Soloway M: Intravesical therapy for bladder cancer. Expert Opin. Pharmacother. 11(6), 947-958 (2010).
74. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE: Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br. J. Urol. 75(2), 180-184 (1995).
75. Schenk-Braat EA, Bangma CH: Immunotherapy for superficial bladder cancer. Cancer Immunol. Immunother. 54(5), 414-423 (2005). (Pubitemid 40543681)
76. Stein JP, Lieskovsky G, Cote R, et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001). (Pubitemid 32120143)
77. Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361(9373), 1927-1934 (2003).
78. Millikan R, Siefker-Radtke A, Grossman HB: Neoadjuvant chemotherapy for bladder cancer. Urol. Oncol. 21(6), 464-467 (2003). (Pubitemid 38542724)
79. Grossman HB, Dinney CP: If cystectomy is insufficient, what is an urologist to do? Urol. Oncol. 21(6), 475-478 (2003). (Pubitemid 38542726)
80. Luo Y, Chen X, ODonnell MA: Role of Th1 and Th2 cytokines in BCG-induced IFN-g production: cytokine promotion and simulation of BCG effect. Cytokine 21(1), 17-26 (2003). (Pubitemid 36369372)
81. Saint F, Patard JJ, Maille P, et al.: T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J. Urol. 166(6), 2142-2147 (2001). (Pubitemid 33065239)
82. Leibovici D, Grossman HB, Dinney CP, et al.: Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J. Clin. Oncol. 23(24), 5746-5756 (2005).
83. Chen M, Hildebrandt MA, Clague J, et al.: Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev. Res. 3(10), 1235-1245 (2010).
84. Sakano S, Wada T, Matsumoto H, et al.: Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br. J. Cancer 95(5), 561-570 (2006). (Pubitemid 44325895)
85. Daly AK: Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010).
86. Penney KL, Pyne S, Schumacher FR, et al.: Genome-wide association study of prostate cancer mortality. Cancer Epidemiol. Biomarkers Prev. 19(11), 2869-2876 (2010).
87. Huang YT, Heist RS, Chirieac LR, et al.: Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 27(16), 2660-2667 (2009).
88. Azzato EM, Pharoah PD, Harrington P, et al.: A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 19(4), 1140-1143 (2010).
89. Park JH, Wacholder S, Gail MH, et al.: Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42(7), 570-575 (2010).
90. Wu X, Lin J, Grossman HB, et al.: Projecting individualized probabilities of developing bladder cancer in white individuals. J. Clin. Oncol. 25(31), 4974-4981 (2007). (Pubitemid 350220430)
91. Lin J, Kadlubar FF, Spitz MR, Zhao H, Wu X: A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 14(7), 1832-1836 (2005). (Pubitemid 40995103)
92. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I: Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol. Biomarkers Prev. 16(4), 815-819 (2007). (Pubitemid 46650587)
93. Wu X, Amos CI, Zhu Y, et al.: Telomere dysfunction: a potential cancer predisposition factor. J. Natl Cancer Inst. 95(16), 1211-1218 (2003). (Pubitemid 37069551)
94. Willeit P, Willeit J, Mayr A, et al.: Telomere length and risk of incident cancer and cancer mortality. JAMA 304(1), 69-75 (2010).
95. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA: A catalog of published genome-wide association studies www.genome.gov/gwastudies